microtubule associated protein 1AGenealiases: MAP1L · MTAP1A
Q-omics provides the consensus-scored MAP1A profile across patient tissues and cancer cell-line models. MAP1A expression is associated with patient survival in 26 of 34 cancer types, with the highest sampling consensus in UVM. Among the 18 cancer types available for tumor–normal comparison, MAP1A is differentially expressed in 13, with the highest sampling consensus in BLCA. Additionally, MAP1A protein abundance shows 31,896 significant protein co-abundance associations, with the highest sampling consensus in GBM. Together, these results highlight UVM, BLCA, and GBM as cancer lineages where MAP1A shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for MAP1A — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes MAP1A survival associations across molecular data types. MAP1A RNA expression shows survival associations in the most cancer types (26), followed by mutation status (12) and mass-spec protein abundance (6). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible MAP1A RNA expression–survival associations across cancer types. High MAP1A expression shows unfavorable associations in UVM, BLCA, KICH and OV, but favorable associations in ACC and LGG. The UVM Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify UVM as the clearest survival context for MAP1A RNA expression.
This table summarizes MAP1A tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 13, while mass-spec protein shows differences in 5. The strongest signals are observed in THCA for RNA and COAD for protein.
This table ranks reproducible tumor–normal expression differences for MAP1A. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. MAP1A shows lower tumor expression in BLCA, THCA and COAD and higher tumor expression in LIHC, KIRP and CHOL. The BLCA box plot shows higher MAP1A RNA expression in normal versus tumor tissue (log2 FC = −3.795, t-test p < 0.001).
This table shows molecular features associated with MAP1A in patient tissues and cancer cell lines. In patient samples, MAP1A shows the broadest associations at the RNA and protein expression levels, with GBM recurring as the lineage with the largest associated feature set. In cancer cell lines, MAP1A RNA and mutation anchors are most strongly linked to RNA-expression features, especially in BONE, while CRISPR and shRNA rows add functional-dependency signals in BLOOD_Leukemia and UPPER_AERODIGESTIVE_TRACT.
